ABVC BioPharma, Inc. (ABVC)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Sep 30, 2017
Biotechnology (Startups)		509.59K	152.43K	969.78K	355.80K	483.05K
Biotechnology (Startups) Growth		234.31%	-84.28%	172.57%	-26.34%	-31.16%
Total		509.59K	152.43K	969.78K	355.80K	483.05K
Total Growth		234.31%	-84.28%	172.57%	-26.34%	-31.16%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Sep 30, 2017
USA		509.59K	152.43K	969.78K	355.80K	483.05K
USA Growth		234.31%	-84.28%	172.57%	-26.34%	-31.16%
Total		509.59K	152.43K	969.78K	355.80K	483.05K
Total Growth		234.31%	-84.28%	172.57%	-26.34%	-31.16%

Data Source: S&P Global Market Intelligence Last updated: Mar 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error